home · filing · 0001213900-24-094622
8-K filed November 5, 2024, 6:59 PM ET
ticker ATNM
CIK 0001388320
leadership
confidence high
sentiment neutral
materiality 0.35
Actinium appoints June Almenoff, M.D., Ph.D. to Board of Directors
Actinium Pharmaceuticals, Inc.
Dr. Almenoff brings over 25 years of biopharma leadership; previously President and CMO of Furiex (acquired by Actavis/AbbVie for $1.2B).
She will serve on the Nominating and Corporate Governance Committee; term as Class III director expires at 2025 annual meeting.
Granted options for 50,000 shares at $1.71, vesting 28% at 12 months then 2% monthly thereafter.
Appointment effective November 1, 2024; experienced in translational medicine, clinical development, and regulatory submissions.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2024-11-01
Filed November 5, 2024, 6:59 PM ET
On November 1, 2024, June Almenoff, M.D., Ph.D., was appointed as a director of Actinium Pharmaceuticals, Inc. (the “Company”)
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
June Almenoff was appointed as Director at Actinium Pharmaceuticals, Inc..
Action appointed
Role Director
Exact text from the filing
On November 1, 2024, June Almenoff, M.D., Ph.D., was appointed as a director of Actinium Pharmaceuticals, Inc. (the “Company”)
View on SEC.gov
Source: SEC EDGAR
accession 0001213900-24-094622
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.